HM
NBIX icon

HealthCor Management’s Neurocrine Biosciences NBIX Stock Holding History

HealthCor Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.39M Sell
20,000
-1,720
-8% -$201K 2.19% 8
2022
Q3 		$2.31M Buy
+21,720
New +$2.2M 0.29% 49
2022
Q2 		– Sell
-23,480
Closed -$2.2M – 67
2022
Q1 		$2.2M Sell
23,480
-342,257
-94% -$29M 0.15% 51
2021
Q4 		$31.1M Sell
365,737
-80,002
-18% -$7.36M 1.7% 23
2021
Q3 		$42.8M Buy
445,739
+55,759
+14% +$5.27M 1.84% 22
2021
Q2 		$38M Buy
+389,980
New +$37.4M 1.52% 25
2021
Q1 		– Sell
-226,460
Closed -$21.7M – 96
2020
Q4 		$21.7M Sell
226,460
-700,610
-76% -$67.7M 0.84% 37
2020
Q3 		$89.1M Buy
927,070
+571,300
+161% +$66.1M 3.57% 15
2020
Q2 		$43.4M Sell
355,770
-1,191,970
-77% -$132M 1.82% 26
2020
Q1 		$134M Buy
1,547,740
+740,876
+92% +$72.5M 5.73% 5
2019
Q4 		$86.7M Sell
806,864
-686,616
-46% -$71.9M 3.09% 12
2019
Q3 		$135M Sell
1,493,480
-877,910
-37% -$82M 5.09% 2
2019
Q2 		$200M Buy
2,371,390
+855,300
+56% +$70.2M 7.77% 1
2019
Q1 		$134M Buy
1,516,090
+747,460
+97% +$62.5M 5.4% 5
2018
Q4 		$54.9M Buy
768,630
+358,274
+87% +$34.3M 1.72% 24
2018
Q3 		$50.5M Sell
410,356
-383,599
-48% -$43.5M 1.67% 26
2018
Q2 		$78M Buy
793,955
+102,360
+15% +$9.16M 2.48% 15
2018
Q1 		$57.4M Sell
691,595
-833,405
-55% -$70.4M 1.95% 18
2017
Q4 		$118M Sell
1,525,000
-562,110
-27% -$38.3M 3.85% 11
2017
Q3 		$128M Sell
2,087,110
-463,068
-18% -$24.4M 4.29% 6
2017
Q2 		$117M Buy
2,550,178
+1,325,178
+108% +$64.3M 4.23% 7
2017
Q1 		$53M Buy
1,225,000
+236,100
+24% +$10.1M 2.43% 13
2016
Q4 		$38.3M Buy
+988,900
New +$44.8M 2.16% 18
2016
Q3 		– Sell
-450,000
Closed -$20.5M – 48
2016
Q2 		$20.5M Sell
450,000
-275,000
-38% -$12.7M 1.12% 28
2016
Q1 		$28.7M Buy
+725,000
New +$28.8M 1.62% 20
2015
Q4 		– Sell
-150,000
Closed -$5.97M – 48
2015
Q3 		$5.97M Buy
+150,000
New +$7.25M 0.34% 35

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HealthCor Management's NBIX Position: Q4 2022 in Review

HealthCor Management reduced its Neurocrine Biosciences (NBIX) stake by 7.9% in Q4 2022, selling an estimated $201K and leaving 20,000 shares worth $2.39M. The position accounts for 2.19% of the portfolio, ranked #8.

HealthCor Management first reported a position in NBIX in Q3 2015 and has held it in 26 quarters since. The position peaked at $200M in Q2 2019. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • HealthCor Management held 20,000 shares of Neurocrine Biosciences worth $2.39M as of Q4 2022.
  • HealthCor Management sold 1,720 Neurocrine Biosciences shares in Q4 2022, an estimated $201K.
  • Neurocrine Biosciences made up 2.19% of HealthCor Management's portfolio in Q4 2022, its #8 holding.
  • HealthCor Management first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 26 quarters since.
  • HealthCor Management's Neurocrine Biosciences position peaked at $200M in Q2 2019.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.